In this study, we demonstrated that EZH2 inhibition by chidamide disrupted the activity of Smo/Gli-1 pathway and downstream signaling molecule p-AKT and increased the adriamycin sensitivity of AML cells and stem/progenitor cells. Here, EZH2 is linked to acute myeloid leukemia.